Utilization of a novel siRNA platform technology to target APOE in the brain for the treatment of Alzheimer’s Disease
We identified a potent CASi against APOE with no unwanted effects on liver APOE levels or peripheral cholesterol. The molecule holds promise as a future therapeutic for ε4 carriers suffering from MCI/AD, many of whom are contraindicated for the currently approved immunotherapies.
Authors
- Maxine Nelson (ORCID: https://orcid.org/0000-0003-1990-5099)
- Akila Ram (ORCID: https://orcid.org/0000-0003-1511-3983)
- Shilpi Mahajan
- Craig Blanchette (ORCID: https://orcid.org/0000-0003-4560-9613)
- Lisa Scherer (ORCID: https://orcid.org/0000-0002-5019-171X)
- R. Joel Duff (ORCID: https://orcid.org/0000-0003-3810-8036)
- Donald Button
- Marina Kovaliov (ORCID: https://orcid.org/0000-0002-4837-7654)
- Kaylin Hwang
- Clara Tourino
- Anindya Bhattacharya
- Charles Allerson
- Abhinav Kumar
- Dee Datta
- Li Li
- Priya Pulya
- Priyanka Singh
- Alex Embusch
Institutions
- Switch (CH)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_105053
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00